Tectonic Therapeutic develops protein and antibody drugs that act on G protein coupled receptors, led by a candidate for pulmonary hypertension. TECX reports earnings on Thu, Nov 5, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in TECX, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | UBS | Initiated | Hold | |
| Aug 7 | Wells Fargo | Maintained | Buy | |
| May 26 | Raymond James | Upgrade | Buy | |
| Apr 14 | Stifel | Initiated | Buy | |
| Jun 11 | Raymond James | Reinstated | Buy |
Whale Options Flow
90DNo whale options trades in TECX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TECX is in one of them and how their past TECX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TECX in an article yet. Here's the latest on the wider market.
About Tectonic Therapeutic
Tectonic Therapeutic is a biotechnology company based in Watertown, Massachusetts. It develops therapeutic proteins and antibodies that act on G protein coupled receptors, a family of cell surface molecules that help control many body functions. Its lead candidate, TX45, is a relaxin based molecule being tested for pulmonary hypertension linked to heart and lung disease. The company's work is aimed at patients with serious conditions where treatment options are limited.
- Headquarters
- Watertown, MA